PK Bio is working towards developing innovative oral medicines targeting to improve the health of patients with neurodegenerative diseases. PK Bios’ innovative medicines are targeted against selective cell death signaling molecules, which are involved in the cell survival and apoptotic cell death observed in many neurodegenerative disorders including Amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s and Huntington diseases. PK Bios’ small molecule therapeutics candidates provide a novel neuroprotective and anti-neuroinflammatory approach designed to maximize clinical outcome and limit off-target effects.
PK Bio is a private held company with corporate values. We strive for excellence, high level of productivity, conduct with integrity & high ethical standards. We respect the functional expertise and role of our colleagues. We value diversity in culture, experiences and work style.